Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2011, Article ID 724871, 11 pages
Review Article

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?

Multiple Sclerosis Clinic and Neuro-Immunology Laboratory, Department of Medicine, University of British Columbia, Room S-159, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2H5

Received 23 November 2010; Accepted 27 February 2011

Academic Editor: Mark S. Freedman

Copyright © 2011 Mona Alkhawajah and Joel Oger. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.